Increased metabolism to dihydrodigoxin after intake of a microencapsulated formulation of digoxin

Summary A capsule preparation containing small, enteric-coated granules of digoxin was developed to prevent acid hydrolysis of the drug in the stomach and to diminish the variation in plasma glycoside concentration during the intervals between doses. The absorption and metabolism of tritiated digoxin after a single oral loading dose of this formulation (Formulation C) were compared to those after ingestion of a digoxin solution (Formulation S) by 8 healthy men. Drug concentrations were measured by radioimmunoassay (RIA) and liquid chromatography (LC). The percentage of the digoxin dose excreted in the urine during 72 h, as measured by RIA, was significantly lower after the capsule (20.5±2.0% vs 36.2±3.0% after S, mean±SEM) but total urinary radioactivity after the two treatments was similar (C 35.3±5.2 and S 41.2±2.6%; p>0.05). The discrepancy was mainly due to significantly greater excretion of dihydrodigoxin after the capsule ( 12.8%, range 0–28.6% of the dose) than after the digoxin solution ( 5.4%, range 0–14.5%). Dihydrodigoxin was not measured by the RIA. The recovery of hydrolysis metabolites (LC) was greater during the first 24 h after S (2.3±0.6% vs 0.9±0.3% after C; p<0.05). The peak plasma concentration of digoxin (RIA) was significantly reduced and delayed after intake of C (2.5±0.4 nmol/l at 3.8±0.3 h vs. 8.3±0.8 nmol/l at 0.9±0.1 h after S), and so was the shortening of electromechanical systole at 1.5 h, 2.5 h, and 3 h. Thus, the enteric-coated digoxin preparation delayed the absorption and reduced the hydrolysis of the glycoside, but it also carried the drawback of reducing digoxin availability, mainly because of increased metabolism to dihydrodigoxin.     

Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene

Summary The pharmacodynamics and pharmacokinetics of the combination of furosemide retard (30 mg)/triamterene (50 mg) were compared with furosemide (30 mg) in 18 healthy male volunteers aged 39.3±6.3 years. After the administration of furosemide the onset of its effect was very rapid, reaching a maximum between 1.5 to 3 h, and followed by rebound after 9 to 10.5 h. In contrast the combination furosemide retard/triamterene showed a protracted course with a duration of effect up to 12 h. The general effect over 12 h of the two preparations was equivalent with respect to the excretion of urine, sodium, chloride and calcium, but the combination caused significantly less excretion of potassium (p0.05) than furosemide. After a lag-phase of 33.9±5.4 min the maximum plasma concentration of furosemide was reached after 3.47±0.66 h, and the elimination half-life was approximately 2 h. After a lag-phase of 33.0±17.8 min the maximum plasma concentration of the main metabolite of triamterene, the OH-TA sulphuric acid ester, was reached after 1.7±0.59 h, and its elimination half-life amounted to 1.25±0.37 h. Because of the sustained release of furosemide from the retard-formulation, its principal pharmacokinetic parameters were better adapted to those of triamterene. The consequences were not only a protracted effect but also an improved electrolyte profile, especially with regard to reduced loss of potassium. In the case of renal insufficiency, however, the potassium level in serum might be increased to an undesirable extent.     

Immunohistochemistry of folliculo-stellate cells in normal human adenohypophyses and in pituitary adenomas

Summary Presence and distribution of S-100 protein (S-100), neuron-specific enolase (NSE), cytokeratin polypeptides, glial fibrillary acidic protein (GFAP), vimentin, actin, lysozyme and pituitary hormones (prolactin, hGH, ACTH, -FSH, -LH, -TSH, alpha subunit) in folliculo-stellate cells (FSC) were studied in seven normal human pituitary glands and 28 pituitary adenomas using peroxidase-antiperoxidase and the avidin-biotin immunohistochemical techniques. Approximately 5% of the cells of the adenohypophysis were agranular, non-hormon-producing FSC most of which showed a conspicuous and strong reaction with S-100 antibodies but some were, in addition, GFAP- and vimentin-positive. In contrast to endocrine cells (EC), FSC were not decorated by antibodies to NSE or cytokeratins. In addition to supportive functions, these cells, due to their close special relationship to EC, seem to have transport and other metabolic functions yet to be elucidated. By their S-100 reactivity and their distribution FSC are comparable to glial cells of the central and schwann and satellite cells of the peripheral nervous system (PNS) as well as to supportive cells in neuroendocrine organs and related tumors (e.g., pheochromocytomas, paragangliomas, carcinoids). With one exception, S-100 reactive FSC were not found in pituitary adenomas. The immunohistochemical demonstration of S-100 protein in pituitary tissue is, therefore, a reliable aid in the discrimination between adenomas and normal pituitary tissue, particularly in small and poorly preserved specimens. In one adenoma FSC were found in addition to ACTH-producing tumor cells. This seems to be an extremely rare event suggesting a combination tumor.Supported in part by Fonds zur Förderung der wissenschaftlichen Forschung (no. 4708) to H. Denk     

冷诱导RNA结合蛋白在放射性肺损伤模型中的表达变化

目的 探讨冷诱导RNA结合蛋白（CIRBP）在放射性肺损伤模型中的表达变化。方法 将30只雄性C57BL/6小鼠按体重随机分为2组,每组15只,对照组小鼠不做任何处理,模型组小鼠经20 Gy X射线单次胸部照射,构建放射性肺损伤模型,于照射后5周解剖。采用苏木素-伊红（H&E）染色和Masson染色观察肺组织病理改变及胶原的沉积;采用免疫组织化学法检测肺组织炎症因子白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）的表达;采用qRT-PCR技术检测肺组织中CIRBP mRNA的表达;采用免疫荧光技术和Western blotting技术检测肺组织中CIRBP蛋白的表达。结果 与对照组相比,模型组肺组织血管扩张充血、炎细胞浸润、部分肺泡间隔增厚,IL-6的表达[（187.22 ±34.77) vs (129.41 ±5.58),t = 3.179,P < 0.05]和TNF-α的表达[（187.02 ±19.16 )vs (137.52 ±23.53),t = 5.069,P < 0.05]均升高,差异具有统计学意义,而且模型组肺组织中CIRBP mRNA的表达明显升高[（1.97 ±0.39) vs (1 ±0.08),t = 3.45,P < 0.05]。除此之外,免疫荧光和Western blot结果显示模型组CIRBP蛋白表达均明显升高[（14.76 ±1.61) vs (9.32 ±1.26),t = 3.751,P < 0.05;(1.49 ±0.14) vs (1.13 ±0.17),t = 2.819,P < 0.05],差异具有统计学意义。结论 CIRBP在放射性肺损伤模型中的表达明显升高,其可能是放射性肺损伤过程中的重要促炎因子。     

糖化血红蛋白、空腹及服糖后2小时胰岛素水平与高血压发病风险的前瞻性研究

目的 探讨糖化血红蛋白(Glycosylated hemoglobin,HbA1c)、空腹胰岛素(Fasting insulin,INS)及服糖后2小时胰岛素(Insulin 2 hours after oral glucose tolerance test,INS-2H)与高血压发病的风险。方法 本研究采用全人群多阶段整群随机抽样方法,抽取了贵州省12个区(县)的48个乡镇共9 280人进行调查,排除基线HbA1c、INS及INS-2H缺失及有高血压病史者,最终纳入1 684例进入分析。中位随访6.23年。采用Cox生存回归分析HbA1c、INS及INS-2H与高血压发病的相关性。PAF及Survival计算人群归因危险百分比。结果 HbA1c和INS-2H每升高一个单位,高血压发病风险分别增加31.5%和1.1%。HbA1c高水平组发病风险是低水平组的2.87倍。相比第一分位组,INS-2H第四分位组发病风险增加73.6%。HbA1c水平控制在6.3 mmol/L及以下可降低人群8.6%的发病。INS-2H水平分别控制在8.81 mIU/L、15.60 mIU/L、24.30 mIU/L以下,可降低人群22.6%、11.9%和6.8%的发病。年龄>42岁组的人群中,HbA1c高水平组发病风险是低水平组的2.84倍; INS-2H第二、三、四分位组发病风险分别是第一分位组的2.001倍、2.145倍和2.145倍。男性人群中,HbA1c高水平组发病风险是低水平组的2.760倍; INS-2H第三、四分位组发病风险是第一分位组的1.828倍和2.116倍。结论 HbA1c及INS-2H是高血压发病的危险因素,在年龄>42岁和男性人群更为敏感。控制HbA1c及INS-2H能有效降低人群高血压发病。     

泽漆水提物对香烟烟雾诱导小鼠慢性阻塞性肺病及肺组织癌前病变相关蛋白的影响

目的：探究泽漆水提物对香烟烟雾(CS)所致的慢性阻塞性肺病(COPD)的保护作用及肺组织癌前病变相关蛋白的影响。方法：通过建立CS所致的COPD小鼠模型(60只),随机分为正常组、模型组、阳性药组(地塞米松2 mg·kg^-1)及泽漆水提物低、中、高剂量组(1.875、3.75、7.5 g·kg^-1)。采用高效液相色谱法(HPLC)测定泽漆水提物中相关成分;动物肺功能仪检测小鼠呼气末期暂停(EEP)、气道阻力(Penh)、50%肺活量呼吸时的呼气流量(EF50)等肺功能指标变化;高通量液相蛋白芯片技术检测小鼠肺泡灌洗液(BALF)中白细胞介素(IL)-2、IL-5、IL-18、IL-17A、IL-27等炎性因子水平变化;苏木素-伊红(HE)染色检测小鼠肺组织的病理变化;比色法测定小鼠肺组织中的丙二醛(MDA)、髓过氧化物酶(MPO)及谷胱甘肽过氧化物酶(GSH-Px)含量变化;实时荧光定量聚合酶链式反应(Real-time PCR)检测肿瘤坏死因子-α(TNF-α)、转化生长因子-β(TGF-β)、基质金属蛋白酶(MMP)-2、MMP-9及MM...     

黄芪桂枝五物汤加减对糖尿病大鼠坐骨神经细胞凋亡相关Bax和Caspase-12的影响

目的 研究黄芪桂枝五物汤加减对糖尿病大鼠坐骨神经细胞凋亡相关B细胞淋巴瘤-2相关X蛋白（Bax）和胱天蛋白酶-12（Caspase-12）蛋白与mRNA表达的影响,以探究黄芪桂枝五物汤加减治疗糖尿病周围神经病变的作用机制。方法 选用动物实验方法进行研究,将60只雄性SD大鼠通过高糖高脂饲料喂养联合链尿佐菌素（STZ）腹腔注射诱导成糖尿病大鼠动物模型,连续3 d随机血糖≥16.7 mmol·L^-1者为糖尿病大鼠造模成功,将48只造模成功的糖尿病大鼠随机分为模型组、α-硫辛酸组（0.026 8 g·kg^-1·d^-1）、中药高、低剂量组（2.5、1.25 g·kg^-1·d^-1）,每组各12只,并设正常组10只。监测大鼠体质量和随机血糖水平;干预16周末通过Key point肌电采集系统检测大鼠坐骨神经传导速度;分别通过蛋白免疫印迹法（Western blot）和实时荧光定量聚合酶链式反应（Real-time PCR）检测大鼠坐骨神经中Bax和Caspase-12蛋白与mRNA的表达。结果 与正常组比较,模型组大鼠体质量显著下降（P<0.01）,随机血糖水平显著升高（P<0.01）;干预16周,与模型组比较,中药高剂量组大鼠体质量明显升高（P<0.05）,其他给药组体质量变化差异无统计学意义;各给药组随机血糖水平均显著降低（P<0.01）。与正常组比较,干预16周,模型组大鼠运动和感觉神经传导速度显著降低（P<0.01）;与模型组比较,各给药组大鼠运动和感觉神经传导速度均明显升高（P<0.05,P<0.01）。与正常组比较,模型组大鼠坐骨神经Bax和Caspase-12蛋白表达显著升高（P<0.01）;与模型组比较,各给药组大鼠坐骨神经Bax和Caspase-12蛋白表达均显著降低（P<0.01）。与正常组比较,模型组大鼠坐骨神经Bax和Caspase-12 mRNA表达显著升高（P<0.01）;与模型组比较,α-硫辛酸组、中药高剂量组大鼠坐骨神经Bax mRNA表达明显降低（P<0.05,P<0.01）,中药低剂量组坐骨神经Bax mRNA表达降低有下降趋势;各给药组大鼠坐骨神经Caspase-12 mRNA表达显著降低（P<0.01）。结论 黄芪桂枝五物汤加减可能通过抑制坐骨神经细胞凋亡来改善和修复糖尿病大鼠坐骨神经损伤。     

血清脂联素、骨桥蛋白和HE4在子宫内膜癌患者中的表达及意义

目的：探讨血清脂联素（APN）、骨桥蛋白（OPN）和人附睾分泌蛋白4(HE4)在子宫内膜癌患者中的表达及意义。方法：选取2019年11月至2022年9月郴州市第一人民医院收治的子宫内膜癌患者62例（子宫内膜癌组）,另选取同期50例子宫内膜不典型增生患者（内膜增生组）和50例健康志愿者（正常内膜组）。检测并比较三组血清APN、OPN、HE4水平,采用受试者工作特征（ROC）曲线分析血清APN、OPN、HE4对子宫内膜癌的诊断效能,并采用Spearman相关性分析探讨血清APN、OPN、HE4与临床病理特征的相关性。结果：子宫内膜癌组患者血清APN水平低于内膜增生组和正常内膜组,OPN、HE4水平高于内膜增生组和正常内膜组。国际妇产科联盟（FIGO）分期为Ⅲ期患者血清APN水平低于Ⅱ期和Ⅰ期患者,OPN、HE4水平高于Ⅱ期和Ⅰ期患者;肌层浸润深度≥1/2肌层患者血清APN水平低于<1/2肌层患者,OPN、HE4水平高于<1/2肌层患者;淋巴结转移患者血清APN水平低于无淋巴结转移患者,OPN、HE4水平高于无淋巴结转移患者,差异均具有统计学意义（P <0.05）。ROC曲...     

错配修复蛋白表达缺失在子宫内膜癌中的临床病理意义

目的:探究错配修复(MMR)蛋白表达缺失在子宫内膜癌(EC)中的临床病理意义。方法:选取惠州市第一人民医院2019年3月至2022年12月收集的EC患者术后石蜡包埋子宫内膜组织标本50例,采用免疫组织化学检测法检测MMR蛋白表达,包含MLH1、MSH2、MSH6及PMS2,观察MMR蛋白表达缺失率,对不同年龄及EC病理特征的MMR蛋白表达缺失情况进行比较。结果:(1)50例EC患者MMR蛋白表达缺失发生率为36.00%。MMR蛋白MLH1、MSH2、PMS2、MSH6表达缺失率分别为22.00%、6.00%、30.00%、6.00%,其中单项缺失4例(8.00%),两项表达缺失14例(18.00%)。(2)≤50岁EC患者MMR蛋白缺失表达率(56.00%)高于> 50岁EC患者(16.00%),差异具有统计学意义(P <0.05)。(3)不同细胞分化程度、肌层浸润程度及淋巴结转移情况患者MMR蛋白表达缺失情况比较,差异均无统计学意义(P> 0.05)。结论:MMR蛋白在EC中表达缺失率较高,以PMS2表达缺失为主,且MMR蛋白表达缺失率在≤50岁EC患者中更高,故需...